{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:41:16Z","timestamp":1752669676863,"version":"3.37.3"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester NIHR Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018754","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biologic and nonbiologic immunomodulators, used to treat immune-mediated inflammatory diseases (IMIDs), could impair the immune response to COVID-19 vaccines and thus vaccine effectiveness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our objective was to investigate the association between biologic and nonbiologic immunomodulators and seroconversion following the first and second dose of COVID-19 vaccines in patients with IMIDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum samples were collected following the first or second dose of the BNT162b2 or AZD1222 vaccines from patients receiving biologic and\/or nonbiologic immunomodulators for one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease or systemic lupus erythematosus. Seroconversion was defined as a positive Roche Elecsys\u00ae Anti-SARS-CoV-2 S (spike protein subunit S1\/receptor binding domain) immunoassay (\u2265 0.8\u2005U mL\u20131). Association between immunomodulator exposure and seroconversion was assessed using logistic regression, adjusting for age and sex.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After excluding those with prior COVID-19, post-first vaccine dose samples from 193 participants and post-second dose samples from 312 participants were included in the analysis. Following the first vaccine dose, 17.6% (n = 34) of participants did not seroconvert. Seroconversion was reduced for those on nonbiologic [adjusted odds ratio (OR) 0.29, 95% confidence interval (CI) 0.12\u20130.69] or combined nonbiologic and biologic treatment (adjusted OR 0.14, 95% CI 0.045\u20130.45) compared with those on biologic monotherapy. Subgroup analysis demonstrated reduced odds of seroconversion in those on methotrexate (adjusted OR 0.097, 95% CI 0.19\u20130.49) or prednisolone treatment (adjusted OR 0.044, 95% CI 0.002\u20131.00) relative to tumour necrosis factor-\u03b1 inhibitor monotherapy. No participants receiving rituximab (n &amp;lt; 5) seroconverted after the first vaccine dose. Following the second vaccine dose, 1.6% of all participants did not seroconvert. Non-seroconversion was associated with receiving rituximab (n = 3 of 4) compared with those receiving other therapies (n = 2 of 308, P &amp;lt; 0.001). Post hoc analyses demonstrated that non-seroconversion was associated with age [adjusted OR 0.18, 95% CI 0.037\u20130.93 for those aged 60\u2005years and over (reference category age 18\u201339\u2005years)], but not sex, ethnicity or vaccine type.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with nonbiologics, particularly methotrexate, is associated with impaired seroconversion following two BNT162b2 or AZD1222 vaccine doses, in patients with IMIDs. These findings are consistent with those of other published studies. While this could indicate reduced protection against COVID-19, the immunological parameters that correlate most closely with vaccine effectiveness need to be defined to reach this conclusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljac109","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:20:26Z","timestamp":1674224426000},"page":"542-551","source":"Crossref","is-referenced-by-count":2,"title":["The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-0556","authenticated-orcid":false,"given":"Ali","family":"Al-Janabi","sequence":"first","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-2573","authenticated-orcid":false,"given":"Amelle","family":"Ra","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Littlewood","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2680-750X","authenticated-orcid":false,"given":"Amy C","family":"Foulkes","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamish J A","family":"Hunter","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-1288","authenticated-orcid":false,"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[{"name":"National Institute of Health Research, Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester NHS Foundation Trust , Manchester , UK"},{"name":"Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Salford , UK"},{"name":"Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A","family":"Moriarty","sequence":"additional","affiliation":[{"name":"Affinity Biomarker Labs, Translation & Innovation Hub Building, Imperial College London White City Campus , London W12 0BZ , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[{"name":"National Institute of Health Research, Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester NHS Foundation Trust , Manchester , UK"},{"name":"Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester , Oxford Road, Manchester M13 9PL , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-6251","authenticated-orcid":false,"given":"Jimmy K","family":"Limdi","sequence":"additional","affiliation":[{"name":"Section of IBD, Division of Gastroenterology, Northern Care Alliance NHS Trust , Manchester , UK"},{"name":"Manchester Academic Health Science Centre, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-4427","authenticated-orcid":false,"given":"Christopher E M","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"2023100916153315300_ljac109-B1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"key":"2023100916153315300_ljac109-B2","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100916153315300_ljac109-B3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100916153315300_ljac109-B4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"author":"GOV.UK Coronavirus (COVID-19) in the UK","key":"2023100916153315300_ljac109-B5"},{"key":"2023100916153315300_ljac109-B6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"2023100916153315300_ljac109-B7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","article-title":"COVID-19: risk for cytokine targeting in chronic inflammatory diseases?","volume":"20","author":"Schett","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2023100916153315300_ljac109-B8","doi-asserted-by":"crossref","first-page":"e490\u2013e506","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023100916153315300_ljac109-B9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"Manisty","year":"2021","journal-title":"Lancet"},{"key":"2023100916153315300_ljac109-B10","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100916153315300_ljac109-B11","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"2023100916153315300_ljac109-B12","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.cgh.2022.02.030","article-title":"Effectiveness and curability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis","volume":"20","author":"Jena","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023100916153315300_ljac109-B13","doi-asserted-by":"crossref","first-page":"e627\u2013e37","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023100916153315300_ljac109-B14","doi-asserted-by":"crossref","first-page":"e42\u2013e52","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023100916153315300_ljac109-B15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","volume":"185","author":"Al-Janabi A, Littlewood Z, Griffiths CEM","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023100916153315300_ljac109-B16","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1111\/ajt.16701","article-title":"Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients","volume":"21","author":"Cucchiari","year":"2021","journal-title":"Am J Transplant"},{"key":"2023100916153315300_ljac109-B17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"2023100916153315300_ljac109-B18","first-page":"e778\u2013e88","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023100916153315300_ljac109-B19","doi-asserted-by":"crossref","first-page":"e21\u2013e31","DOI":"10.1016\/S2666-5247(21)00275-5","article-title":"T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study","volume":"3","author":"Angyal","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023100916153315300_ljac109-B20","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMc2102051","article-title":"Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Bradley","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100916153315300_ljac109-B21","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1136\/ard.2011.152983","article-title":"Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice","volume":"70","author":"Ribeiro","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"R2","key":"2023100916153315300_ljac109-B22","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2023100916153315300_ljac109-B23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023100916153315300_ljac109-B24","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2023100916153315300_ljac109-B25","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.vaccine.2018.07.039","article-title":"The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis","volume":"36","author":"van Aalst","year":"2018","journal-title":"Vaccine"},{"key":"2023100916153315300_ljac109-B26","first-page":"898","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023100916153315300_ljac109-B27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","article-title":"Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial","volume":"81","author":"Araujo","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023100916153315300_ljac109-B28","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2023100916153315300_ljac109-B29","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023100916153315300_ljac109-B30","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023100916153315300_ljac109-B31","article-title":"Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab","volume":"13","author":"Lin","year":"2022","journal-title":"Nat Commun"},{"key":"2023100916153315300_ljac109-B32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.gastro.2021.10.029","article-title":"Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNF\u03b1","volume":"162","author":"Edelman-Klapper","year":"2022","journal-title":"Gastroenterology"},{"key":"2023100916153315300_ljac109-B33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S2468-1253(22)00005-X","article-title":"COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case\u2013control study","volume":"7","author":"Alexander","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023100916153315300_ljac109-B34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2021.09.055","article-title":"Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"162","author":"Sakuraba","year":"2022","journal-title":"Gastroenterology"},{"key":"2023100916153315300_ljac109-B35","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann Intern Med"},{"author":"Our World in Data","key":"2023100916153315300_ljac109-B36"},{"key":"2023100916153315300_ljac109-B37","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/ibd\/izac082","article-title":"Humoral immunogenicity of 3 COVID-19 messenger RNA vaccine doses in patients with inflammatory bowel disease","volume":"28","author":"Schell","year":"2022","journal-title":"Inflam Bowel Dis"},{"key":"2023100916153315300_ljac109-B38","article-title":"Serological responses to the first three doses of SARS-CoV-2 vaccination in \u00adinflammatory bowel disease: a prospective cohort study","volume":"2022","author":"Quan","year":"2022","journal-title":"medRxiv"},{"key":"2023100916153315300_ljac109-B39","doi-asserted-by":"crossref","first-page":"e177\u2013e187","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023100916153315300_ljac109-B40","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/annrheumdis-2021-222096","article-title":"Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases","volume":"81","author":"Aikawa","year":"2022","journal-title":"Ann Rheum Dis"},{"first-page":"480","year":"2022","author":"Aikawa","key":"2023100916153315300_ljac109-B41"},{"author":"Oxford Clinical Trials Research Unit (OCTRU)","key":"2023100916153315300_ljac109-B42"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac109\/48885686\/ljac109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/4\/542\/51961123\/ljac109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/4\/542\/51961123\/ljac109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:22:16Z","timestamp":1696868536000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/4\/542\/6880649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,7]]},"published-print":{"date-parts":[[2023,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac109","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,12,7]]}}}